Repurposing Initiatives Proposed To Unlock ‘Untapped Potential’ In Europe
Medicines For Europe Report Urges Action To Bolster Value Added Medicines
Executive Summary
Earlier industry involvement in repurposing activities and a more tailored European regulatory environment for value added medicines are among the proposals set out in a new report published by Medicines for Europe. The association has also suggested creating an “indications pool” to act as a central repository for repurposing information generated by not-for-profit and academic organizations through a STAMP pilot project.
You may also be interested in...
New €23m EU Research Consortium To Accelerate Repurposing
REMEDi4ALL is the latest in a series of European initiatives to develop and centralize drug repurposing R&D. The group will identify, test and validate new indications for existing medicines on top of shaping policies favorable to repurposing.
Stampa Urges Investment In European Manufacturing
Fresh from being named as the new president of Medicines for Europe, Medichem CEO Elisabeth Stampa sets out the association’s priorities around investment in European manufacturing, as well as identifying key obstacles that must be overcome to create a sustainable environment for off-patent medicines, in an exclusive interview with Generics Bulletin.
Dexamethasone Shows Potential Of Repurposed Generics Against COVID-19
Positive trial results for dexamethasone in treating COVID-19 patients demonstrate the potential of repurposing existing generic medicines to fight the coronavirus pandemic.